A new direction for Alzheimers research?


Very interesting study published in Science on Thursday about the effect of bexarotene, a drug indicated for the treatment of cutaneous manifestation of cutaneous T-cell lymphoma now on Eisai's books, to stimulate removal of beta-amyloid in mice. Beta-amyloid accummulation appears to be the main cause of Alzheimer's dementia. Clinical trials in people of course will take years but at least that is one promising ‘candidate' Alzheimer drug after years of failures – Pfizer/Medivation's Dimebon and Lilly's Semagacestat being two of these!